The observed six-fold enrichment of p.R414X in breast cancer patients is in line with previous findings for other PALB2 founder mutations26–28 and in the upper range of the overall mutational effect size in PALB2 case-control sequencing studies29,30. The gene discussed is PALB2; the disease is breast carcinoma.